Immune checkpoint inhibitors (ICIs) have revolutionized medical practice in oncology since
the FDA approval of the first ICI 11 years ago. In light of this, Lymphocyte-Activation Gene 3 …

Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple
biological activities over T cell activation and effector functions. LAG-3 plays a regulatory …

Highlights•LAG-3 is a highly important next-generation immune checkpoint molecule.•Ninety-
seven clinical trials are evaluating at least 16 LAG-3-targeting molecules.•Here we identify …

Immune checkpoint inhibitors (ICIs) have ushered in a new era of cancer therapy; however,
ICIs are only effective in selective patients. The efficacy of ICIs is closely related to the tumor …

Cancer is the second leading cause of death worldwide. Traditional approaches, such as
surgery, chemotherapy, and radiotherapy have been the main cancer therapeutic modalities …

Recent studies highlight the importance of baseline functional immunity for immune
checkpoint blockade therapies. High‐dimensional systemic immune profiling is performed in …

Many cancer patients do not benefit from PD-L1/PD-1 blockade immunotherapies. PD-1 and
LAG-3 co-upregulation in T-cells is one of the major mechanisms of resistance by …

While promising, PD-L1 expression on tumor tissues as assessed by immunohistochemistry
has been shown to be an imperfect biomarker that only applies to a limited number of …

Background Improving cancer immunotherapy long-term clinical benefit is a major priority. It
has become apparent that multiple axes of immune suppression restrain the capacity of T …

CX3CL1 is one of the 50 up-to-date identified and characterized chemokines. While other
chemokines are produced as small, secreted proteins, CX3CL1 (fractalkine) is synthetized …